Pfizer SG&A Expenses 2010-2024 | PFE
Pfizer annual/quarterly sg&a expenses history and growth rate from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Pfizer sg&a expenses for the quarter ending September 30, 2024 were $3.244B, a 1.13% decline year-over-year.
- Pfizer sg&a expenses for the twelve months ending September 30, 2024 were $15.031B, a 1.28% increase year-over-year.
- Pfizer annual sg&a expenses for 2023 were $14.771B, a 8% increase from 2022.
- Pfizer annual sg&a expenses for 2022 were $13.677B, a 7.67% increase from 2021.
- Pfizer annual sg&a expenses for 2021 were $12.703B, a 9.54% increase from 2020.
Pfizer Annual SG&A Expenses
(Millions of US $) |
| 2023 |
$14,771 |
| 2022 |
$13,677 |
| 2021 |
$12,703 |
| 2020 |
$11,597 |
| 2019 |
$12,726 |
| 2018 |
$12,612 |
| 2017 |
$14,804 |
| 2016 |
$14,844 |
| 2015 |
$14,809 |
| 2014 |
$14,097 |
| 2013 |
$14,355 |
| 2012 |
$15,171 |
| 2011 |
$17,581 |
| 2010 |
$18,973 |
| 2009 |
$14,752 |
Pfizer Quarterly SG&A Expenses
(Millions of US $) |
| 2024-09-30 |
$3,244 |
| 2024-06-30 |
$3,717 |
| 2024-03-31 |
$3,495 |
| 2023-12-31 |
$4,575 |
| 2023-09-30 |
$3,281 |
| 2023-06-30 |
$3,497 |
| 2023-03-31 |
$3,418 |
| 2022-12-31 |
$4,645 |
| 2022-09-30 |
$3,391 |
| 2022-06-30 |
$3,048 |
| 2022-03-31 |
$2,593 |
| 2021-12-31 |
$4,104 |
| 2021-09-30 |
$2,899 |
| 2021-06-30 |
$2,923 |
| 2021-03-31 |
$2,777 |
| 2020-12-31 |
$3,739 |
| 2020-09-30 |
$2,658 |
| 2020-06-30 |
$2,659 |
| 2020-03-31 |
$2,541 |
| 2019-12-31 |
$2,616 |
| 2019-09-30 |
$3,260 |
| 2019-06-30 |
$3,511 |
| 2019-03-31 |
$3,339 |
| 2018-12-31 |
$2,164 |
| 2018-09-30 |
$3,494 |
| 2018-06-30 |
$3,542 |
| 2018-03-31 |
$3,412 |
| 2017-12-31 |
$4,555 |
| 2017-09-30 |
$3,504 |
| 2017-06-30 |
$3,430 |
| 2017-03-31 |
$3,315 |
| 2016-12-31 |
$4,429 |
| 2016-09-30 |
$3,559 |
| 2016-06-30 |
$3,471 |
| 2016-03-31 |
$3,385 |
| 2015-12-31 |
$5,049 |
| 2015-09-30 |
$3,270 |
| 2015-06-30 |
$3,386 |
| 2015-03-31 |
$3,104 |
| 2014-12-31 |
$3,981 |
| 2014-09-30 |
$3,556 |
| 2014-06-30 |
$3,520 |
| 2014-03-31 |
$3,040 |
| 2013-12-31 |
$4,152 |
| 2013-09-30 |
$3,395 |
| 2013-06-30 |
$3,591 |
| 2013-03-31 |
$3,217 |
| 2012-12-31 |
$4,047 |
| 2012-09-30 |
$3,491 |
| 2012-06-30 |
$3,665 |
| 2012-03-31 |
$3,968 |
| 2011-12-31 |
$3,821 |
| 2011-09-30 |
$4,457 |
| 2011-06-30 |
$4,800 |
| 2011-03-31 |
$4,503 |
| 2010-12-31 |
$5,197 |
| 2010-09-30 |
$4,599 |
| 2010-06-30 |
$4,774 |
| 2010-03-31 |
$4,403 |
| 2009-12-31 |
$5,244 |
| 2009-09-30 |
$3,282 |
| 2009-06-30 |
$3,350 |
| 2009-03-31 |
$2,876 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$142.241B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
